Tag archive for ‘reldesemptiv in SMA’
Cytokinetics: Update based on 2Q, 2018 Conference Call (CYTK, Buy, $6.85)
Investment Thesis Omecamtiv is the Essence of the Investment Thesis I continue to believe that Cytokinetics is an attractive investment based on the potential for omecamtiv mecarbil, which promises to bring an important new mechanism of action to the treatment of congestive heart failure. If the ongoing phase 3, GALACIC-HF trial (a massive 8,000 patient […]